Back to search results

Transcranial Direct Current Stimulation for Chemotherapy-Induced Peripheral Neuropathy

This study is looking at how well transcranial direct current stimulation (tDCS) can help cancer survivors who have chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes numbness, tingling, pain, and movement problems after chemotherapy. tDCS is a non-invasive way to stimulate the brain. Researchers believe it might improve sensation and reduce pain. You may be able to join if you are a cancer survivor between 18 and 85 years old, have CIPN, and are not currently receiving chemotherapy, radiation, or immunotherapy. The study will measure how well you can detect vibrations at 2 and 3 weeks to see if the treatment is successful. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 50 participants. It compares transcranial direct current stimulation (tDCS) to a sham procedure.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, vibration detection threshold, is measured at weeks 2 and 3 after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07673614

Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

Not Yet Recruiting
NAAges 18–85InterventionalSupportive care
University of Michigan Rogel Cancer Center
~50 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:Sham InterventionSurvey AdministrationTranscranial Direct Current Stimulation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Vibration detection threshold
Measured over at weeks 2 and 3

Conditions

Chemotherapy-Induced Peripheral Neuropathy
Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Chemotherapy-Induced Peripheral NeuropathyHematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Brendan L McNeish · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center

Who to contact

Eshaka Eshwar
[email protected]
734-232-5901
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 to 85 years of age
Diagnosis of cancer, stages I-IV
Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)
Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy
CIPN20 score ≥ 20
Able to walk unassisted
Proficient in English

Exclusion

Known brain metastases
Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)
History of brain or spinal surgery
Neuropathy other than CIPN
Significant hearing or vision deficits
Vestibulopathy
Currently receiving chemotherapy, radiation therapy, or immunotherapy
Contraindications to transcranial direct current stimulation (tDCS), including recent seizures
Presence of metallic objects in the head
Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)
Active scalp dermatological conditions

What this trial measures

  • Vibration detection thresholdat weeks 2 and 3

    Assessed via Vibration Detection Threshold (CASE IV): Quantitative sensory testing (QTS) for large fiber function. Will conduct a series of two-way analysis of variance (ANOVAs) with each of the vibratory thresholds, cold thresholds, and physical function measures as the dependent variables. Group (active transcranial direct current stimulation \[tDCS\] versus sham tDCS) and time (baseline, immediate post) will be included as fixed factors of interest along with their interaction to assess treatment effects over time.